Battipaglia, Giorgia <br/><br/>
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.  [electronic resource] 

 -  Clinical lymphoma, myeloma & leukemia  08 2019 
 - 506-508 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2152-2669 
<br/><br/><label>Standard No.: </label>10.1016/j.clml.2019.04.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Cohort Studies<br/>Combined Modality Therapy<br/>Feasibility Studies<br/>Female<br/>Follow-Up Studies<br/>Hematopoietic Stem Cell Transplantation--mortality<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Maintenance Chemotherapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Prognosis<br/>Protein Kinase Inhibitors--therapeutic use<br/>Remission Induction<br/>Sorafenib--therapeutic use<br/>Survival Rate<br/>Transplantation, Homologous<br/>Young Adult<br/>fms-Like Tyrosine Kinase 3--antagonists & inhibitors